1. Coronary CT angiography: All subjects who meet inclusion criteria for a percutaneous liver biopsy, are consented to phase II, and do not have known CAD defined as prior percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) or have not undergone CCTA within the previous 12 months, will undergo a CCTA with CAC score. Subjects undergoing this portion of the analysis will need a renal function panel within 30 days of the scan date with a glomerular filtration rate (GFR) of ≥ 60 mls/min/1.73m2 by the Cockcroft-Gault equation, no prior history of an allergic reaction to intravenous CT contrast, and no contraindications to administration of sublingual nitroglycerin and nodal blocking agents. All CCTA scans will be analyzed by a cardiologist with level III ACC/ACR certified imaging expertise in accordance with the Society of Cardiovascular Computed Tomography (SCCT) guidelines. Scans will be performed in accordance with SCCT guidelines. Studies will be obtained utilizing a 128-slice dual source scanner with a high pitch, single heart beat image acquisition capabilities (Somatom Definition Flash CT®, Siemens, Erlagen, Germany). CAC scanning will occur first at a standard tube voltage of 120 keV and 3 mm slice acquisition and CareDose® modulation of tube current enabled for all scans. CT technologist will be responsible for contacting the on-call CT imaging specialist for CAC score ≥400 prior to proceeding to CCTA acquisition. Continuation to CCTA will be at the discretion of the CT imaging specialist. Tube voltage and image acquisition protocoling will be selected by the CT technologist in consultation with the on-call cardiac CT imaging specialist in accordance with the flowsheet depicted in Appendix 3. Tube voltage of 120keV will be used for BMI > 30 and lowered to 100keV for BMI ≤ 30. CareDose® modulation of tube current will be enabled for all scans. Pretreatment with nodal blocking agents will be as follows: for HR < 70 bpm and systolic blood pressure (SBP) > 100 mm Hg will be given 50mg orally, for HR > 70 bpm and SBP > 100 mm Hg will be given 100mg orally, and nodal blocker will be held for patients with HR < 50 bpm or SBP < 100 mm Hg at the time of evaluation. Additional nodal blocker will be administered following initial dosing at the discretion of the cardiac imaging specialist. All subjects with SBP > 90 mm Hg and without a history of phosphodiesterase inhibitor usage in the preceding 72 hours received nitroglycerin spray 0.4-0.8 mg within 2 minutes of scan acquisition. High-pitched, prospective, ECG-triggered helical scanning will be performed with heart rate (HR) < 60 bpm and HR variability < 5 beats or with HR < 60 bpm at the discretion of the imaging specialist. The remaining scans will be performed using prospective, ECG triggering acquisition centered at 70%-phase with between 10-20% padding (40-80% of the R-R interval). Visapaque® intravenous (IV) contrast will be used for all scans. A triphasic injection protocol consisting of 75mL of IV contrast followed by 40 mL of 50% contrast mixed with normal saline chased with normal saline at a flow rate of 5 mL/second will be used for all scans with total IV contrast volume of 105-125 mL. Contrast flow rates will be increased to 6 ml/second for patients with BMI > 30. Coronary artery stenosis by CCTA will be determined on a per-patient and per-vessel basis using an 18 segment model in accordance with SCCT guidelines for interpretation. The major epicardial coronary arteries (left main, left anterior descending, left circumflex, and right coronary arteries) will be graded for severity of CAD, defined as obstructive CAD (>50% stenosis), non-obstructive CAD (≤50% stenosis), or no CAD (vessels free of angiographic evidence of disease), respectively. The posterior descending artery will be included in the left circumflex or right coronary artery groups depending on its origin. The subject will have the option of declining the CCTA and CAC scan. Subjects with known CAD as defined on recent prior CCTA (within last 12 months) will not undergo CCTA, but their CAD history and/or prior CCTA results will be included in the analysis.